PTC Therapeutics ( (PTCT) ) has issued an update.
PTC Therapeutics announced its financial results for the fourth quarter and full year 2024, reporting a total revenue of $807 million for the year, exceeding its guidance. The company achieved all its clinical and regulatory milestones on schedule, including four NDA submissions accepted for filing, and closed a license and collaboration agreement with Novartis for its Huntington’s disease program. Despite a decrease in total revenue compared to 2023, PTC’s commercial team delivered strong performance, and the company ended the year with over $2 billion in cash, providing a solid foundation for future growth.
More about PTC Therapeutics
PTC Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company is involved in the development of treatments for genetic disorders, oncology, and infectious diseases, with a strong emphasis on rare diseases.
YTD Price Performance: 11.07%
Average Trading Volume: 709,732
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $3.93B
Find detailed analytics on PTCT stock on TipRanks’ Stock Analysis page.